Bakkt Announces Pricing of $75 Million Public Offering
Clear Street LLC and Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, are acting as joint book-running managers of the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-288361) declared effective by the Securities and Exchange Commission (the 'SEC') on July 3, 2025. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available, from the SEC's website at http://www.sec.gov, from Clear Street LLC, Attention: Syndicate, 4 World Trade Center 150 Greenwich St Floor 45 New York, NY 10007, or by email at syndicate@clearstreet.io and from Cohen & Company Capital Markets, Attention: Prospectus Department, 3 Columbus Cir, New York, NY 10019, or by email at capitalmarkets@cohencm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. Bakkt will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Bakkt
Founded in 2018, Bakkt builds solutions that enable our clients to grow with the crypto economy. Through institutional-grade trading and onramp capabilities, our clients leverage technology that's built for sustainable, long-term involvement in crypto.
Bakkt is headquartered in Alpharetta, GA. For more information, visit: https://www.bakkt.com/ |
@Bakkt | LinkedIn
Bakkt-C
Cautionary Note Regarding Forward-Looking Statements
This release contains 'forward-looking statements' within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities and Exchange Act of 1934, as amended. Such statements include, but are not limited to, statements regarding the offering. Forward-looking statements can be identified by words such as 'will,' 'likely,' 'expect,' 'continue,' 'anticipate,' 'estimate,' 'believe,' 'intend,' 'plan,' 'projection,' 'outlook,' 'grow,' 'progress,' 'potential' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. Such forward-looking statements are based upon the current beliefs and expectations of the Company's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and beyond the Company's control.
Actual results and the timing of events may differ materially from the results anticipated in such forward-looking statements as a result of the following factors, among others: the Company's ability to continue as a going concern; the Company's ability to grow and manage growth profitably; the possibility that the Company may be unable to obtain the applicable regulatory approvals to execute on the cooperation agreement with Distributed Technologies Research Global Ltd. ('DTR'); finalizing the proposed commercial agreement with DTR, including whether such agreement will be executed on terms favorable to the Company or if at all, or be completed on the expected timeline, and whether the Company will be able to successfully integrate its operations with those of DTR, including its infrastructure, and achieve the expected benefits therefrom; the regulatory environment for crypto currencies and digital stablecoin payments; changes in the Company's business strategy, including its adoption of its updated investment policy ('Investment Policy') as described in the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the 'SEC') on June 10, 2025 (the 'June 10, 2025 8-K'); the price of digital assets, including Bitcoin; risks associated with owning digital assets, including Bitcoin, including price volatility, limited liquidity and trading volumes, relative anonymity, potential widespread susceptibility to market abuse and manipulation, compliance and internal control failures at exchanges and other risks inherent in its entirely electronic, virtual, form and decentralized network; the fluctuation of the Company's operating results, including because the Company may be required to account for its digital assets at fair value; the Company's ability to time the price of its purchase of digital assets pursuant to its strategy; the impact of the market value of digital assets on the Company's ability to satisfy its financial obligations, including any debt financings; unrealized fair value gains on its digital asset holdings subjecting the Company to the corporate alternative minimum tax; legal, commercial, regulatory and technical uncertainty regarding digital assets and enhanced regulatory oversight of companies holding digital assets including the possibility that regulators reclassify any digital assets the Company holds, including Bitcoin, as a security causing the Company to be in violation of securities laws and be classified as an 'investment company' under the Investment Company Act of 1940; competition by other Bitcoin treasury companies and the availability of spot-traded products for Bitcoin; enhanced regulatory oversight as a result of the Company's Investment Policy; the possibility of experiencing greater fraud, security failures or operational problems on digital asset trading venues compared to trading venues for more established asset classes, and any malfunction, breakdown or abandonment of the underlying blockchain protocols, or other technological difficulties, may prevent access to or use of such digital assets; the concentration of the Company's expected digital asset holdings relative to non-digital assets; the inability to use the Company's digital asset holdings as a source of liquidity to the same extent as cash and cash equivalents, due to, for example, risks associated with digital assets and other risks inherent to its entirely electronic, virtual form and decentralized network; the Company or a third-party service provider experiencing a security breach or cyber-attack where unauthorized parties obtain access to its digital assets; the loss of access to or theft or data loss of the Company's digital assets, which could be unrecoverable due to the immutable nature of blockchain transactions; if the Company elects to hold its digital assets through a third-party custodian, the loss of direct control over its digital assets and dependence on the custodian's security practices and operational integrity which may lead to the loss of its digital assets as a result of the insolvency of the custodian, theft by employees or insiders of the custodian or if the custodian's security measures are comprised, including as a result of a cyber-attack; the Company not being subject to the legal and regulatory protections applicable to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers; the non-performance, breach of contract or other violations by counterparties assisting the Company in effecting its Investment Policy; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs and continued access to the line of credit with Intercontinental Exchange Holdings, Inc.; changes in the market in which the Company competes, including with respect to its competitive landscape, technology evolution or changes in applicable laws or regulations; changes in the markets that the Company targets; volatility and disruptions in the crypto, digital payments and stablecoin markets that subject the Company to additional risks, including the risk that banks may not provide banking services to the Company and market sentiments regarding crypto currencies, digital payments and stablecoins; the possibility that the Company may be adversely affected by other macroeconomic, geopolitical, business, and/or competitive factors; the Company's ability to launch new services and products, including with its expected commercial partners, or to profitably expand into new markets and services; the Company's ability to execute its growth strategies, including identifying and executing acquisitions and divestitures and the Company's initiatives to add new clients; the Company's ability to reach definitive agreements with its expected commercial counterparties; the Company's ability to successfully complete a strategic transaction of the Loyalty business; the Company's failure to comply with extensive government regulations, oversight, licensure and appraisals; uncertain and evolving regulatory regime governing blockchain technologies, stablecoins, digital payments and crypto; the Company's ability to establish and maintain effective internal controls and procedures; the exposure to any liability, protracted and costly litigation or reputational damage relating to the Company's data security; the impact of any goodwill or other intangible assets impairments on the Company's operating results; the Company's ability to maintain the listing of its securities on the New York Stock Exchange; and other risks and uncertainties indicated in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K for the year ended December 31, 2024 and its most recent quarterly report on Form 10-Q for the quarter ended March 31, 2025, and the risks regarding the Company's adoption of its Investment Policy set forth in Exhibit 99.1 to the June 10, 2025 8-K.
You are cautioned not to place undue reliance on such forward-looking statements. Such forward-looking statements relate only to events as of the date on which such statements are made and are based on information available to us as of the date of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
28 minutes ago
- CBC
As Detroit 3 automakers report tariff blows, experts say a trade deal is the only solution
The Detroit Three automakers are taking a big hit from the Trump administration's tariffs, and industry experts say only one thing can stop the bleeding for the North American auto industry — a trade deal with low tariff rates for the industry. General Motors, Ford and Stellantis have all reported tariff impacts in the billions on recent earnings calls. Ford said on Wednesday that it took an $800-million US (about $1.1 billion Cdn) hit for the second quarter as a result of tariffs. Ford CEO Jim Farley said the company is in daily contact with the White House, with an ultimate goal of reducing its tariff costs, especially on parts tariffs. "We see there's a lot of upside depending on how the negotiation goes with the administration," Farley said. This comes after General Motors said last week that tariffs cost the company $1.1 billion US (about $1.52 billion Cdn) in its second quarter. Chief financial officer Paul Jacobson said the tariff impact for the full year could reach $4 or $5 billion US, though GM is working to offset that with "manufacturing adjustments, targeted cost initiatives and consistent pricing." "Over time, we remain confident that our total tariff expense will come down as bilateral trade deals emerge and our sourcing and production adjustments are implemented," Jacobson said on the company's quarterly earnings call. On its own earnings call on Tuesday, Stellantis also said tariffs were having a major impact, and could add up to the tune of 1.5 billion euros (about $2.4 billion Cdn) this year. Since April, a 25 per cent tariff rate on all finished cars going into the U.S. has applied, regardless of what country they're made in. But under the Canada-United States-Mexico trade agreement (CUSMA), that rate only applies to the non-U.S. content of a car. So far, that cost hasn't made its way into car prices — GM said pricing "remains stable" for the second quarter, and added pricing assumptions for North America for the rest of the year are unchanged. Ford also said it expected net pricing to remain "flat." Industry analyst Sam Fiorani said it isn't entirely surprising that companies are choosing to eat the cost of tariffs thus far. "The car companies can't really push the tariffs through directly yet, because we're in this period of flux, we don't know what the end point will be," Fiorani said. Raising prices by 10 or 15 per cent for now and then lowering them if tariffs come back down isn't an option, he explained, because any customers who just bought the car when it was at the higher rate would be upset with the change. If they do raise any prices, that would have to be longer term. Autoworkers feeling the impact While folks buying cars have been spared the cost of tariffs for the time being, workers in the auto industry haven't been so lucky. Lana Payne, national president of Unifor, which represents some 40,000 autoparts and assembly workers in Canada, says tariffs have resulted in lost work and investment within Canada. In May, GM laid off 750 autoworkers at its Oshawa, Ont., plant when it cut a shift. Windsor's Stellantis assembly plant is also alternating between full production levels, a reduced schedule and full shutdowns throughout the summer. And Stellantis's Brampton, Ont., plant also paused retooling in recent months, with workers there recently telling media they were growing increasingly concerned about when work would resume. "The carnage is building up," Payne said. "Pretty much across the entire auto sector, there has been an impact of some kind or another, depending on the facility and the community." WATCH | Auto expert discusses Windsor Assembly Plant's future given Stellantis earnings: The Windsor Assembly Plant could be in trouble if tariffs don't disappear, as company posts losses: Auto expert 9 days ago The Windsor Assembly Plant could be in serious trouble if tariffs don't go away, a leading automotive expert says, as U.S. President Donald Trump renews threats of tariffs. It comes as the company says preliminary estimates show a nearly $4-billion loss in the first half of this year. The CBC's Katerina Georgieva reports. If tariffs on autos are here to stay, Payne says she expects more of these production cuts and pauses to pile up. That's why she says it's "crucial" that a trade deal between Canada and the U.S. sets tariffs on autos at zero — something she's been working to articulate to folks in government. "We've been very clear to the government what our red lines are," Payne said. "Even though we're facing a deadline right now of August 1st … we're much better off having no deal than a bad deal that will result in a continued bleed of investment and jobs out of this country." Only thing that will help is a trade deal While he doesn't have a prediction for Canada's trade deal, president and CEO of Global Automakers of Canada David Adams says he hopes the rate will be zero, at the very least for CUSMA-compliant cars and parts. "The reality is that any tariff is problematic," Adams said. "If you start doing the math … you're talking, you know, billions [of] dollars per year in terms of the extra cost associated with the tariff." At any rate higher than zero, he says automakers would slowly start to shift production to the U.S. Adams says it won't necessarily be easy to strike an agreement, and that Canada should be very careful about what it puts on the table, given the free trade deal between the U.S., Canada and Mexico is up for review in 2026. So far, goods that are subject to that deal have been sheltered from any tariffs, which has helped Canada weather the tariff storm. WATCH | Why the American auto industry needs the Canadian market: Why the American auto industry needs the Canadian market 28 days ago "We don't have a lot of cards to play, and we need to play the cards that we do have very carefully and strategically," Adams said. Given that the European Union and Japan recently reached deals with the U.S. that will allow those countries to sell products to Americans at a 15 per cent rate, Fiorani says he expects cars and parts not covered by CUSMA might face a similar rate. Fiorani said the deals with the EU and Japan are a sore spot for car companies and suppliers in North America, given that rates for cars coming from Europe or Japan are lower than the 25 per cent currently on cars from Canada. "These are companies that have built their business case on shipping parts across the border. And now they're competing with vehicles that are coming from either the EU, U.K. or Japan, with potentially a lower tariff than they're currently applying to Canadian parts and vehicles," Fiorani said. That said, Fiorani points out that the deals that U.S. President Donald Trump has struck so far are still "handshakes at best," as none of them have yet been signed on paper, which means that reality could still change. In the long term, Greig Mordue, an associate professor at McMaster University in Hamilton, says putting any kinds of tariffs on the auto sector would be a dismantling of the last 60 years of North America's joint auto industry. And while that won't happen overnight, Mordue says Canada will need to find ways to distance itself from the U.S. in the long run. He added that while the Detroit Three have been the focus of the auto sector in North America historically, they don't produce as many cars in Canada anymore. And of the 1.3 million cars made here in 2024, 533,000 were Toyotas and 420,550 were Honda models. Given that, and the global shift from gas-powered cars to electric vehicles, he says Canada should try to find partnerships abroad.
CBC
28 minutes ago
- CBC
This is the court case that could kneecap most Trump tariffs
Most of the tariffs that U.S. President Donald Trump has imposed on countries around the world face a crucial legal test on Thursday. The hearing before the U.S. Court of Appeal for the Federal Circuit involves a pair of lawsuits challenging the 25 per cent tariff Trump levied on imports from Canada and Mexico in March and what Trump called his "Liberation Day" tariffs, imposed on nearly every other country in April. At issue is whether Trump's justifications for the tariffs hold any legal water, given the president has limited powers to levy duties on foreign countries. Canada is watching the case closely because of its implications for the tariffs Trump imposed ostensibly to combat cross-border fentanyl trafficking — tariffs that he's threatening to raise to 35 per cent on Friday. Todd Tucker, director of industrial policy and trade at the Roosevelt Institute, a Washington think-tank, says the legal challenge to Trump's tariffs has global economic implications. "Trump is disrupting global trade relations in a way that we haven't seen since the 1930s," Tucker said in an interview with CBC News. WATCH | Carney on European Union's trade deal with U.S.: Carney says Canada is 'in a different position' than EU on trade deal with U.S. 3 days ago When asked by a reporter if Canada could see a similar trade deal with the United States as the European Union's, which includes a 15 per cent tariff, Prime Minister Mark Carney said Europe and Canada have different relationships with the U.S., particularly because the U.S. needs Canadian energy. "Some kind of favourable, even partial victory for the plaintiffs in these cases will sort of put the global economy back on a more secure footing," he said. The case, which has moved further through the courts than any other legal challenge of Trump's tariffs, brings together two related lawsuits: Five small businesses, led by a New York wine importer, challenging the Liberation Day tariffs. Twelve states, led by Oregon, challenging both the Liberation Day tariffs and the tariffs on Canada and Mexico. Both sets of plaintiffs won their case at the U.S. Court of International Trade in late May. That ruling found the president overstepped his authority under the International Emergency Economic Powers Act (IEEPA), the statute Trump used to impose both sets of tariffs. Oral arguments take place Thursday in the Trump administration's appeal of that ruling Jeffrey Schwab, senior counsel at Liberty Justice Center, a non-profit public interest litigation firm representing the five small businesses, says the case aims to rein in what he describes as presidential overreach. "The case is about whether the president has the power to unilaterally impose tariffs on any country he wants, at any rate he wants, at any time he wants, for any reason he wants," said Schwab in an interview with CBC News. "Congress ultimately has that power under our constitution, and although Congress can delegate that power to the president, they have not done so." Do tariffs 'deal with' fentanyl crisis? The IEEPA gives the president the authority to use emergency economic measures to "deal with any unusual and extraordinary threat … to the national security, foreign policy, or economy of the United States." The Trump administration's argument — both in his executive order levying the tariffs on Canada and in its legal brief filed for the appeal — is that the flow of fentanyl across the country's northern border constitutes that "unusual and extraordinary threat." The administration claimed the tariffs "deal with" the fentanyl threat by giving the U.S. leverage to pressure Canada to address the issue. Trump's justification for the tariffs on Mexico is similar: that drug trafficking and illegal immigration across the southern border constitute an emergency, and that tariffs provide leverage to force the Mexican government to take action. But the Court of International Trade didn't buy those arguments. WATCH | Canada might not get deal on tariffs by deadline, says Trump: Trump says U.S. 'hasn't had a lot of luck with Canada' in trade talks 5 days ago 'Pretty major national significance' The court ruled that the tariffs on Canada and Mexico do not actually deal with the specific threats Trump cited. It also ruled that the "Liberation Day" tariffs were applied too broadly across the globe to be truly addressing an emergency. That ruling struck down both sets of tariffs, but almost immediately, the Trump administration requested and obtained a stay, which meant the tariffs have continued to apply. Molly Nixon, a Washington-based attorney at Pacific Legal Foundation, a national public interest firm, says whichever side wins the appeal, it's very likely headed to the U.S. Supreme Court. "This is a question of pretty major national significance," Nixon told CBC News. "I would be very surprised if the Supreme Court didn't review the case." No president before Trump has used the IEEPA to impose tariffs. His predecessors have used its powers to levy sanctions on enemy regimes, to ban transactions with groups that are deemed terrorist organizations or to freeze the assets of designated transnational criminal organizations. Small business owner 'deeply invested' in case While Canadians are predominantly interested in the case for its impact on the fentanyl tariffs, David Levi, an electrical engineer in Charlottesville, Va., is deeply invested in the "Liberation Day" side of the case. Levi owns MicroKits, a small business that designs and sells make-them-yourself gadget kits and musical instruments. His company is one of the five small-business plaintiffs pursuing the lawsuit. "The tariffs really affect me, because I have to buy parts internationally," Levi said, adding that the high tariff rates announced on Chinese imports and the uncertainty over costs disrupted his business. "My worker who actually puts all the parts together, her hours have been cut 40 per cent and in the last three or four months we've missed out on thousands of units of production," he said. WATCH | Trump press secretary reacts to court ruling on tariffs: White House accuses 'unelected judges' of interfering with Trump's tariff agenda | Power & Politics 2 months ago Appeal court ruling expected within weeks Thursday's hearing is before the U.S. Court of Appeal for the Federal Circuit. The case is moving through the courts at what is, for the U.S. legal system, lightning speed. Legal observers say they expect the appeal court to issue a ruling within weeks, likely by early September. That could soon be followed by the losing party petitioning the U.S. Supreme Court to hear an appeal. The case does not address Trump's 50 per cent tariffs on steel and aluminum imports from around the world, which he imposed using a different statute, the president's long-established power to levy duties on imports for reasons of national security. Other Canadian exports that comply with the rules of origin in the Canada-US-Mexico Agreement are exempt from the fentanyl tariffs, which means .
Globe and Mail
30 minutes ago
- Globe and Mail
Wave (WVE) Q2 Revenue Drops 56%
Key Points Revenue declined sharply to $8.7 million in Q2 fiscal year 2025, missing analyst expectations by 34.1% and falling 55.8% compared to the prior year period. Net loss widened to $50.5 million for Q2 2025, as research and administrative costs increased and Revenue fell to $8.7 million in Q2 2025 from $19.7 million in Q2 2024. Pipeline progress remained robust. These 10 stocks could mint the next wave of millionaires › Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 versus analyst forecasts of $13.2 million and an earnings per share (EPS) loss of $0.31 for Q2 2025, compared to the anticipated loss of $0.28. Revenue fell 55.8% in the second quarter of 2025 compared to the prior year period. Operating expenses rose compared to the same period in 2024 as well, with research and administrative spending increased year over year in Q2 2025, contributing to a higher net loss for the second quarter of 2025 compared to the prior year period. Despite these financial setbacks, the company reported continued pipeline and clinical progress, but the absence of new partnership income and the accelerated cash burn put the focus firmly on near-term trial results and strategy execution. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.31) $(0.28) $(0.25) (24.0%) Revenue (GAAP) $8.7 million $13.2 million $19.7 million (55.8%) Research and Development Expense $43.5 million $40.4 million 7.7% General and Administrative Expense $18.0 million $14.3 million 25.9% Net Loss $(50.5 million) $(32.9 million) (53.5%) Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Strategic Focus Wave Life Sciences is dedicated to developing RNA-based medicines using its proprietary PRISM platform. This technology enables the company to design stereopure oligonucleotides -- specialized, chemically controlled strands of nucleic acids -- allowing greater control over drug properties like efficacy and safety. By leveraging this approach, it aims to create therapies for a wide range of genetic disorders, from rare conditions to broader public health challenges. Recently, Wave Life Sciences has built a diverse portfolio, with candidates in clinical testing for obesity, alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), and Huntington's disease (HD). Success hinges on the advancement of these programs, the validation and expansion of the PRISM platform, and the ability to secure partnerships or licensing deals that can both fund ongoing research and commercialize discoveries. Key Developments in the Quarter The quarter's most immediate headline was the steep drop in revenue, which nearly halved compared to the same period in 2024. No new partnership agreements or large milestone payments offset this gap. At the same time, the company continued to increase research and development spending, which rose approximately 7.7% in the second quarter of 2025 compared to the same period in 2024. General and administrative costs, covering business operations and staff, increased by 25.9% in Q2 2025 compared to Q2 2024, resulting in a net loss of $50.5 million, 53.5% greater than the loss reported in the prior year period. Pipeline progress remained a crucial theme. Wave's PRISM technology continued to support the development of new assets and clinical advances. In AATD, the WVE-006 oligonucleotide program advanced as the company completed multidosing in a 200mg cohort and started single dosing at 400mg. According to management, *RestorAATion-2 clinical data from the complete 200 mg single and multidose cohorts remain on track for Q3 2025; data from the complete 400 mg single dose cohort remain on track for fall 2025.* In obesity, the INLIGHT clinical trial for WVE-007—a GalNAc-conjugated small interfering RNA (siRNA) targeting INHBE mRNA—expanded its second cohort from eight to 32 participants in Q2 2025, based on promising safety and biomarker data. Preclinical data for WVE-007 presented in June 2025 demonstrated efficacy comparable to semaglutide in terms of fat loss, with potential for dosing only once or twice a year. In DMD, the exon-skipping oligonucleotide WVE-N531 produced encouraging results in a 48-week Phase 2 trial, reporting a statistically significant improvement in Time-to-Rise (a measure of muscle function) as well as reduced muscle damage markers. Wave confirmed that its New Drug Application (NDA) filing for WVE-N531 is planned for 2026, citing positive engagement with the U.S. Food and Drug Administration (FDA). For Huntington's disease, the company continues to develop WVE-003, an allele-selective oligonucleotide. Preparation is ongoing for a potentially registrational, global Phase 2/3 study of WVE-003 in adults with SNP3 and Huntington's disease. Strategic partnerships were not a revenue or milestone driver this quarter. Although its collaboration with GSK could result in future milestone payments of up to $3.3 billion, these are not yet factored into its immediate forecasts or cash runway. The company's cash and cash equivalents fell from $302.1 million at December 31, 2024, to $208.5 million at June 30, 2025. Deferred revenue also dropped. Wave also appointed Dr. Christopher Wright as its new Chief Medical Officer to strengthen its clinical and regulatory operations. Looking Ahead The company maintained that it expects to fund its operations into 2027 with current cash resources. However, this forecast does not include possible milestone payments from the GSK partnership and is sensitive to the rate of future cash spending. Continued expense growth or delays in securing new partnerships could affect the duration of its financial runway. Wave Life Sciences did not provide explicit revenue or earnings guidance for upcoming periods. Investors are expected to focus on upcoming clinical readouts, including data from the AATD RestorAATion-2 200mg cohort in the third quarter, INLIGHT obesity trial results later in the year, and the start of pivotal clinical trials in Huntington's disease. Delays or adverse outcomes in these trials, or the absence of new collaboration agreements, could have a significant impact on future financial performance and funding ability. WVE does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 29, 2025
